Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1951
Autohome
ATHM
$2.61B
| $4.29M | ﹤0.01% |
53,600
+45,100
| +531% | +$3.51M |
|
1952
Peoples Financial Services
PFIS
$714M
| $4.27M | ﹤0.01% |
84,881
+15,200
| +22% | +$743K |
|
1953
Boeing
BA
$183B
| $4.27M | ﹤0.01% |
13,111
-63,589
| -83% | -$22.5M |
|
1954
Full House Resorts
FLL
$81.7M
| $4.26M | ﹤0.01% |
1,271,491
+211,747
| +20% | +$616K |
|
1955
Air T
AIRT
$79.2M
| $4.26M | ﹤0.01% |
211,311
-2,200
| -1% | -$45.4K |
|
1956
Heron Therapeutics
HRTX
$63.9M
| $4.25M | ﹤0.01% |
+181,000
| New | +$4M |
|
1957
Factset
FDS
$10.1B
| $4.24M | ﹤0.01% |
15,800
-301,650
| -95% | -$77.5M |
|
1958
TriNet
TNET
$3.16B
| $4.22M | ﹤0.01% |
74,621
-168,479
| -69% | -$9.38M |
|
1959
Cabot Corp
CBT
$4.54B
| $4.21M | ﹤0.01% |
+88,700
| New | +$4.12M |
|
1960
Dawson Geophysical
DWSN
$99.1M
| $4.21M | ﹤0.01% |
1,755,263
+32,489
| +2% | +$75.7K |
|
|
I
1961
DELISTED
INTELSAT S. A.
I
| $4.21M | ﹤0.01% |
+598,466
| New | +$9.41M |
|
1962
Dycom Industries
DY
$12.6B
| $4.2M | ﹤0.01% |
89,099
-206,071
| -70% | -$10M |
|
1963
PENN Entertainment
PENN
$2.52B
| $4.2M | ﹤0.01% |
+164,302
| New | +$3.65M |
|
1964
U-Haul Holding Co
UHAL
$14.4B
| $4.2M | ﹤0.01% |
+111,660
| New | +$4.24M |
|
1965
Acme United Corp
ACU
$232M
| $4.19M | ﹤0.01% |
175,939
+4,639
| +3% | +$98.8K |
|
1966
Yelp
YELP
$1.34B
| $4.18M | ﹤0.01% |
120,000
+49,200
| +69% | +$1.67M |
|
1967
Assembly Biosciences
ASMB
$653M
| $4.18M | ﹤0.01% |
17,012
+6,596
| +63% | +$1.22M |
|
|
LEAF
1968
DELISTED
Leaf Group Ltd.
LEAF
| $4.15M | ﹤0.01% |
1,038,500
+26,200
| +3% | +$96.4K |
|
1969
AC Immune
ACIU
$253M
| $4.15M | ﹤0.01% |
487,402
+107,300
| +28% | +$715K |
|
1970
Ascendis Pharma A/S
ASND
$16.3B
| $4.15M | ﹤0.01% |
29,843
-44,756
| -60% | -$4.97M |
|
|
GHG
1971
GreenTree Hospitality
GHG
$112M
| $4.15M | ﹤0.01% |
377,167
+36,419
| +11% | +$395K |
|
|
VRTV
1972
DELISTED
VERITIV CORPORATION
VRTV
| $4.15M | ﹤0.01% |
210,800
+48,400
| +30% | +$845K |
|
1973
Gildan
GIL
$10.5B
| $4.14M | ﹤0.01% |
140,198
-257,402
| -65% | -$7.53M |
|
1974
CNO Financial Group
CNO
$5.11B
| $4.13M | ﹤0.01% |
227,970
-725,730
| -76% | -$12.3M |
|
1975
Parke Bancorp
PKBK
$413M
| $4.13M | ﹤0.01% |
179,061
+49,684
| +38% | +$1.07M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.